Multifocal Motor Neuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Multifocal Motor Neuropathy Market Outlook
Thelansis’s “Multifocal Motor
Neuropathy Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Multifocal Motor Neuropathy
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Multifocal
Motor Neuropathy Overview
Multifocal
motor neuropathy (MMN), also known as multifocal motor neuropathy with
conduction block (MMNCB), is a rare and acquired form of motor neuropathy
characterized by progressive asymmetric weakness without sensory involvement.
Immune-mediated mechanisms are believed to be the underlying cause of the
disease, as evidenced by the high prevalence of serum IgM anti-GM1 antibodies
in affected individuals and the favourable response to treatment with
intravenous immunoglobulin (IVIG). The concentration of GM1, a ganglioside
found in the myelin of motor nerves, is higher in motor nerves than in sensory
nerves, which may explain the selective motor involvement in MMN. The
conduction block seen in electrophysiological studies in MMN is thought to be
caused by anti-GM1 antibodies, which disrupt the function of sodium and
potassium channels at the nodes of Ranvier, leading to decreased action
potential propagation and reduced conduction velocity. Differential diagnoses
of MMN include ALS, CIDP, and hereditary neuropathy with liability to pressure
palsies (HNPP), radiculopathy, entrapment neuropathies, mononeuritis multiplex,
hereditary motor neuropathies, porphyria, and lead intoxication. The primary
pharmacological treatment option for MMNCB is intravenous immunoglobulin
(IVIG), with a response rate of approximately 80%. In non-responders, treatment
options are limited. The prognosis of MMN is generally good, with most patients
being able to perform activities of daily living and remaining employed. The
disease is rarely fatal due to the sparing of cranial and respiratory muscles.
Complications of treatment, such as thromboembolic events, renal failure,
anaphylactic reactions, and aseptic meningitis, may occur.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment